UPDATE: Jefferies Assumes Icosavax Inc. (ICVX) at Buy, Top Pick

Jefferies analyst Roger Song assumes coverage on Icosavax Inc. (NASDAQ: ICVX) with a Buy rating and a price target of $50.00.

The analyst comments "We like Co’s advantageous/differentiated virus-like particle (VLP) technology. The main value driver is RSV/hMPV program, representing a multi-$B opportunity, with meaningful Ph1b data in 1H22. While not core, we note Co's CV19 vaccine design is similar to/better than Walter Reed’s universal coronavirus vaccine, with initial Ph1/2 data in 1H22."

For an analyst ratings summary and ratings history on Icosavax Inc. click here. For more ratings news on Icosavax Inc. click here.

Shares of Icosavax Inc. closed at $21.98 yesterday.

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'